Cesario Borlongan, MA, PHD




Contact Info MDC 78
12901 Bruce B Downs Blvd
Tampa, FL 33612

Academic Email: cborlong@health.usf.edu

Academic Phone: (813) 974-3988

View My C.V.


  • PHD, Psychology, Keio University, 1994

Interdisciplinary and Emerging Signature Programs

  • Allergy, Immunology & Infectious Disease
  • Biomedical Engineering & Nanomedicine
  • Cancer Biology
  • Cardiovascular Sciences
  • Cellular and Molecular Biology
  • Metabolic Regulation and Disorders
  • Neurodegenerative Disease
  • Neuroscience
  • Women & Children's Health

Research Interests

  • CESAR V. BORLONGAN, Ph.D. is a world leader in stem cell therapy for stroke. His translational bench to clinic research has led to 5 FDA-approved clinical trials of cell transplantation, including the world’s first cell therapy in stroke patients. He served as an NIH Staff Fellow for 5 years, joined the academe in 2002, becoming a Professor in the Department of Neurology at the Medical College of Georgia, with continuous multiple federal funding from VA, DoD, and NIH. He is an author of more than 270 peer-reviewed publications, lead editor of 2 books, and serves as editor of many scientific journals, including Stem Cells, JCBFM, PLoS One, and Brain Research. He is a regular study section member of NIH, VA, and AHA, chairs the State of Maryland Stem Cell Research Funds, among other funding agencies. He serves as Vice President of the International Placenta Stem Cell Society. He was elected in 2012 as AAAS Fellow. He was featured in The Lancet Neurology “Lifeline” of 2008.

Recent Publications

  • Acosta SA, Tajiri N, Shinozuka K, Ishikawa H, Grimmig B, Diamond D, Sanberg PR, Bickford PC, Kaneko Y, Borlongan CV. Long-term upregulation of inflammation and suppression of cell proliferation in the brain of adult rats exposed to traumatic brain injury using the controlled cortical impact model. PloS one. 8(1) : e53376, 2013. http://www.ncbi.nlm.nih.gov/pubmed/23301065
  • Kaneko Y, Tajiri N, Su TP, Wang Y, Borlongan CV. Combination treatment of hypothermia and mesenchymal stromal cells amplifies neuroprotection in primary rat neurons exposed to hypoxic-ischemic-like injury in vitro: role of the opioid system. PloS one. 7(10) : e47583, 2012. http://www.ncbi.nlm.nih.gov/pubmed/23077646
  • Borlongan CV, Rodrigues AA, Oliveira MC. Breaking the barrier in stroke: what should we know? A mini-review. Current pharmaceutical design. 18(25) : 3615-23, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22574976
  • Tajiri N, Lau T, Glover LE, Shinozuka K, Kaneko Y, van Loveren H, Borlongan CV. Cerebral aneurysm as an exacerbating factor in stroke pathology and a therapeutic target for neuroprotection. Current pharmaceutical design. 18(25) : 3663-9, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22574980
  • Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. Current pharmaceutical design. 18(25) : 3670-6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22574981
  • Kaneko Y, Tajiri N, Shinozuka K, Glover LE, Weinbren NL, Cortes L, Borlongan CV. Cell therapy for stroke: emphasis on optimizing safety and efficacy profile of endothelial progenitor cells. Current pharmaceutical design. 18(25) : 3731-4, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22574986
  • Rodrigues MC, Rodrigues AA, Glover LE, Voltarelli J, Borlongan CV. Peripheral nerve repair with cultured schwann cells: getting closer to the clinics. TheScientificWorldJournal. 2012: 413091, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22701355
  • Borlongan CV. The blood brain barrier in stroke. Current pharmaceutical design. 18(25) : 3613-4, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22734824
  • Borlongan CV. Recent preclinical evidence advancing cell therapy for Alzheimer's disease. Experimental neurology. 237(1) : 142-6, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22766481
  • Tajiri N, Acosta S, Glover LE, Bickford PC, Jacotte Simancas A, Yasuhara T, Date I, Solomita MA, Antonucci I, Stuppia L, Kaneko Y, Borlongan CV. Intravenous grafts of amniotic fluid-derived stem cells induce endogenous cell proliferation and attenuate behavioral deficits in ischemic stroke rats. PloS one. 7(8) : e43779, 2012. http://www.ncbi.nlm.nih.gov/pubmed/22912905
  • Lulic D, Burns J, Bae EC, van Loveren H, Borlongan CV. A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury. Neurosurgery. 68(5) : 1172-85; discussion 1185-6, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21307793
  • Borlongan CV, Weiss MD. Baby STEPS: a giant leap for cell therapy in neonatal brain injury. Pediatric research. 70(1) : 3-9, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21659957
  • Borlongan CV. Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all! Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 25(11) : 1674-86, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21727900
  • Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Progress in neurobiology. 95(2) : 213-28, 2011. http://www.ncbi.nlm.nih.gov/pubmed/21903148
  • Yu S, Kaneko Y, Bae E, Stahl CE, Wang Y, van Loveren H, Sanberg PR, Borlongan CV. Severity of controlled cortical impact traumatic brain injury in rats and mice dictates degree of behavioral deficits. Brain research. 1287: 157-63, 2009. http://www.ncbi.nlm.nih.gov/pubmed/19573519
  • Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert review of neurotherapeutics. 8(8) : 1193-201, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18671663
  • Hara K, Yasuhara T, Maki M, Matsukawa N, Masuda T, Yu SJ, Ali M, Yu G, Xu L, Kim SU, Hess DC, Borlongan CV. Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke. Progress in neurobiology. 85(3) : 318-34, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18514379
  • Borlongan CV, Chopp M, Steinberg GK, Bliss TM, Li Y, Lu M, Hess DC, Kondziolka D. Potential of stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinic. Regenerative medicine. 3(3) : 249-50, 2008. http://www.ncbi.nlm.nih.gov/pubmed/18462048